The aim of this study was to determine the subsequent risk of acute urine retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary flow rate of less than 15ml/sec.We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan's National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute urine retention.Prostate su...
Objectives. To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...
OBJECTIVES: To evaluate the management of acute urinary retention (AUR) associated with benign prost...
OBJECTIVES: To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...
Acute urinary retention (AUR) is one of the most significant, uncomfortable and inconvenient event i...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
Acute urinary retention (AUR) is an important complication of benign prostatic hyperplasia (BPH) and...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
OBJECTIVE: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
PURPOSE: We assessed the value of baseline PVR as predictor of the need for invasive therapy during ...
Benign prostatic hyperplasia (BPH) is a disease that affects over 50% of males aged 50 years or old...
Item does not contain fulltextOBJECTIVE: To investigate whether there is a difference in the risk of...
Background: Acute urinary retention (AUR) is one of the most significant complications or long-term ...
Background: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate. This ...
Contains fulltext : 49380.pdf (publisher's version ) (Closed access)PURPOSE: We as...
A significant change has occurred in the management of symptomatic benign prostatic hyperplasia (BPH...
Objectives. To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...
OBJECTIVES: To evaluate the management of acute urinary retention (AUR) associated with benign prost...
OBJECTIVES: To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...
Acute urinary retention (AUR) is one of the most significant, uncomfortable and inconvenient event i...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
Acute urinary retention (AUR) is an important complication of benign prostatic hyperplasia (BPH) and...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
OBJECTIVE: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
PURPOSE: We assessed the value of baseline PVR as predictor of the need for invasive therapy during ...
Benign prostatic hyperplasia (BPH) is a disease that affects over 50% of males aged 50 years or old...
Item does not contain fulltextOBJECTIVE: To investigate whether there is a difference in the risk of...
Background: Acute urinary retention (AUR) is one of the most significant complications or long-term ...
Background: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate. This ...
Contains fulltext : 49380.pdf (publisher's version ) (Closed access)PURPOSE: We as...
A significant change has occurred in the management of symptomatic benign prostatic hyperplasia (BPH...
Objectives. To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...
OBJECTIVES: To evaluate the management of acute urinary retention (AUR) associated with benign prost...
OBJECTIVES: To investigate the prognostic role of prostate-specific antigen (PSA) level and prostate...